Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study

BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte‐colony stimulating factor (PEG‐rhG‐CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang, Hao, Ying, Wang, Lei, Meng, Fanlu, Wen, Fuyu, Zhong, Diansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046050/
https://www.ncbi.nlm.nih.gov/pubmed/33590721
http://dx.doi.org/10.1111/1759-7714.13883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046050/
https://www.ncbi.nlm.nih.gov/pubmed/33590721
http://dx.doi.org/10.1111/1759-7714.13883

Ejemplares similares